| Literature DB >> 34296197 |
Nina G Steele1, Eileen S Carpenter2, Samantha B Kemp3, Veerin R Sirihorachai4, Stephanie The5, Lawrence Delrosario6, Jenny Lazarus6, El-Ad David Amir7, Valerie Gunchick8, Carlos Espinoza6, Samantha Bell6, Lindsey Harris9, Fatima Lima6, Valerie Irizarry-Negron6, Daniel Paglia9, Justin Macchia6, Angel Ka Yan Chu5, Heather Schofield6, Erik-Jan Wamsteker2, Richard Kwon2, Allison Schulman2, Anoop Prabhu2, Ryan Law2, Arjun Sondhi2, Jessica Yu2, Arpan Patel2, Katelyn Donahue4, Hari Nathan6, Clifford Cho6, Michelle A Anderson2, Vaibhav Sahai8, Costas A Lyssiotis3,4,9, Weiping Zou6, Benjamin L Allen1, Arvind Rao4,5,10,11, Howard C Crawford12,13,14, Filip Bednar15, Timothy L Frankel16, Marina Pasca di Magliano17,18,19,20.
Abstract
Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor microenvironment that renders it largely refractory to immunotherapy. We implemented a multimodal analysis approach to elucidate the immune landscape in PDA. Using a combination of CyTOF, single-cell RNA sequencing, and multiplex immunohistochemistry on patient tumors, matched blood, and non-malignant samples, we uncovered a complex network of immune-suppressive cellular interactions. These experiments revealed heterogeneous expression of immune checkpoint receptors in individual patient's T cells and increased markers of CD8+ T cell dysfunction in advanced disease stage. Tumor-infiltrating CD8+ T cells had an increased proportion of cells expressing an exhausted expression profile that included upregulation of the immune checkpoint TIGIT, a finding that we validated at the protein level. Our findings point to a profound alteration of the immune landscape of tumors, and to patient-specific immune changes that should be taken into account as combination immunotherapy becomes available for pancreatic cancer.Entities:
Keywords: CD8+ T cells; Single-cell RNA sequencing; TIGIT; immune checkpoints; pancreatic cancer; tumor immunology
Mesh:
Year: 2020 PMID: 34296197 PMCID: PMC8294470 DOI: 10.1038/s43018-020-00121-4
Source DB: PubMed Journal: Nat Cancer ISSN: 2662-1347